Sumant Ramachandra, ImmPACT Bio CEO

Next-gen CAR-T play­er steps on the gas with a $111M boost and a pos­i­tive glimpse at ear­ly da­ta

Though Imm­PACT Bio was tech­ni­cal­ly found­ed in Is­rael back in 2017, in­com­ing CEO Sumant Ra­machan­dra says the com­pa­ny was re­born last year when it merged with UCLA spin­off Kalthera. Now, with $111 mil­lion more to work with, the new chief ex­ec­u­tive is step­ping on the gas.

Imm­PACT Bio un­veiled a mas­sive Se­ries B round ear­ly Thurs­day morn­ing, along with a C-suite shake­up and a first glimpse at some Phase I da­ta. Sev­en of eight pa­tients with re­lapsed or re­frac­to­ry B cell non-Hodgkin’s lym­phoma giv­en the com­pa­ny’s lead can­di­date — a CD19/CD20 bis­pe­cif­ic CAR-T — achieved com­plete re­mis­sion af­ter a me­di­an fol­low-up of 12 months, Ra­machan­dra said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.